5 July 2019 - - German drugmaker Boehringer Ingelheim and South Korea-based Yuhan Corp. have forged a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule, the companies said.
The collaboration brings together Yuhan Corp.'s expertise in FGF21 biology, obesity and NASH with Boehringer Ingelheim's pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases.
NASH often starts with the accumulation of fat in the liver, giving rise to inflammation and finally leading in many patients to liver fibrosis and cirrhosis.
It has an especially high prevalence among obese and diabetic patients and is an area of high-unmet medical need with no treatments currently available.
Boehringer Ingelheim believes that in many cases approaches targeting one of the features of NASH will not be able to achieve the desired resolution of NASH in patients with advanced stages of the disease.
Thus Boehringer Ingelheim has built a comprehensive program to develop next generation therapy approaches targeting all three key drivers of the disease - steatosis, inflammation and fibrosis.
Preclinical evidence suggests high efficacy, when combining the gut-derived hormone GLP-1 with FGF21.
The dual agonist (GLP1R/FGF21R agonist) is expected to reduce liver cell injury and hepatic inflammation by resolution of steatohepatitis as well as having direct antifibrotic effects and complements Boehringer Ingelheim's R and D portfolio in NASH adding another potential first-in-class opportunity.
Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for patients with cardiometabolic diseases.
It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension, and cardio-renal risk reduction.
The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes as well as contributing factors like obesity.
Yuhan Corp. has over many years been a commercial partner for selected Boehringer Ingelheim cardiovascular and metabolic products in Korea.
Under the terms of the agreement Yuhan Corp. will receive an upfront and near term payments of 40 m and is eligible to receive up to USD 830m in potential milestone payments plus tiered royalties on future net sales.